DOCSLIB.ORG

Estetrol Review: Profile and Potential Clinical Applications

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Estetrol Review: Profile and Potential Clinical Applications CLIMACTERIC 2008;11(Suppl 1):47–58 Estetrol review: profile and potential clinical applications H. J. T. Coelingh Bennink, C. F. Holinka* and E. Diczfalusy{ Pantarhei Bioscience, Zeist, The Netherlands; *PharmConsult1, New York, NY, USA; {Karolinska Institute, Stockholm, Sweden Key words: ESTETROL, E4, REVIEW ABSTRACT In this review paper, the existing information on the human fetal steroid estetrol (E4) has been summarized. In the past, E4 was considered as a weak estrogen and interest disappeared. However, recent new research has demonstrated that E4 is a potent, orally bioavailable, natural human fetal selective estrogen receptor modulator, since it acts in the rat as an estrogen on all tissues investigated except breast tumor tissue, where it has estrogen antagonistic properties in the presence of estradiol. Based on its safety data, its pharmacokinetic properties, its pharmacological profile and the results of first human studies, E4 may be suitable as a potential drug for human use in applications such as hormone replacement therapy (vaginal atrophy, hot flushes), contraception and osteoporosis. Additional areas worth exploring are the treatment of breast and prostate cancer, hypoactive sexual desire disorder and topical use (wrinkles) in women, auto- immune diseases, migraine, cardiovascular applications and the treatment of selected obstetric disorders. For personal use only. was based on previous work, which showed that HISTORY the liver is the exclusive site of 15a- and 16a- 4–6 Estetrol (E4) was discovered by Diczfalusy and hydroxylation . The structural formulae of E4 co-workers in 19651 and was a topic of and other estrogenic steroids are presented in preclinical pharmacological research thereafter Figure 1, demonstrating that these estrogenic for a period of about 20 years. Studies during steroids differ in the number of hydroxyl (OH) that period showed that this estrogenic steroid groups only. molecule has four hydroxyl groups2. Isolation Several ADME (absorption/distribution/meta- and identification of this novel estrogen were bolism/excretion) properties of E4 have been Climacteric Downloaded from informahealthcare.com by University of California Irvine on 11/08/14 achieved by extracting 200 liters of late preg- studied in postmenopausal and last-trimester nancy urine3. On the basis of physical and pregnant women using parenteral administration chemical characteristics, it was concluded that of steroids labeled with radioisotopes7,8. Estetrol the compound was identical with 15a-hydro- was minimally, if at all, metabolized and was not xyestriol (15a-OHE3) or estra-1,3, 5(10)-triene- reconverted to estriol (E3) or estradiol (E2). 3,15a,16a,17b-tetrol3. It was further concluded When injected intravenously to adults, it was that E4 is synthesized exclusively by the fetal liver rapidly and completely excreted in urine as a during human pregnancy, reaching the maternal Ring D monoglucuronide, but otherwise meta- circulation through the placenta. This conclusion bolically unaltered9–11. According to these data, Correspondence: Professor H. J. T. Coelingh Bennink, Pantarhei Bioscience, PO Box 464, 3700 AL Zeist, The Netherlands REVIEW ARTICLE ª 2008 International Menopause Society DOI: 10.1080/13697130802073425 Estetrol review Coelingh Bennink, Holinka and Diczfalusy Figure 1 Structural formulae of estrone (E1), estradiol, (E2), estriol (E3) and estetrol (E4) E4 does not appear to enter the enterohepatic Estetrol produced a number of biological circulation. changes in the rodent uterus, such as weight in- Estetrol was detected in maternal urine as early crease, progesterone receptor stimulation, enzyme as 9 weeks of pregnancy12,13. It was found at high induction, and histological and ultrastructural levels in maternal plasma during the second changes31. It also bound to the human endometrial trimester of pregnancy, with steadily rising con- estrogen receptor. The biochemical, histological centrations of unconjugated E4 to about 1 ng/ml and ultrastructural responses of the immature 14,15 (43 nmol/l) toward the end of pregnancy . rat uterus to E4 revealed a tendency toward For personal use only. Conjugated E4 levels were seven times higher than cell differentiation, in contrast to the typical 16 unconjugated levels . The levels of unconjugated mitotic responses that were observed after E2 32 E4 in fetal plasma at parturition were about 12–19 administration . 17,18 times those in maternal plasma . Amniotic After 20 years of experimental work, E4 fluid levels were about one-third of fetal plasma research was virtually abandoned and ended in levels and five to six times higher than maternal the mid-1980s. Consensus at that time was that, 17,19 plasma levels . Maternal urinary excretion in first, E4 is a weak estrogen and, second, E4 cannot late pregnancy varied between 0.5 and 2.3 mg/ be used as a marker of fetal well-being during day13,20–22. pregnancy due to the high inter- and intra- For follow-up and survey of pregnancy pathol- individual variations in plasma levels14,33. Climacteric Downloaded from informahealthcare.com by University of California Irvine on 11/08/14 ogy, E4 levels were not appropriate due to the However, it seems unlikely that an estrogenic large intra- and inter-individual variations in steroid produced in such significant quantities by plasma levels23–27. the male and female human fetal liver during Competitive receptor binding studies for nucle- pregnancy would have no physiological signifi- ar binding in human proliferative endometrium28 cance. Therefore, in 2001, a project was started at and in rat uterine cytosol29 revealed low estrogen Pantarhei Bioscience to investigate the properties receptor binding affinity for E4, relative to that of E4 with state-of-the-art technologies. of E2. The effects of E when compared to those of 4 SYNTHESIS AND estrone (E1), E2, and E3 on progesterone receptor levels and growth in the human breast cancer cell PHARMACEUTICAL PROPERTIES line MCF-7 revealed that both E3 and E4 behave A new route of synthesis has been developed for as E2 agonists but require substantially higher E4 by Pantarhei, starting with the commercially 30 34 concentrations to achieve the effects of E2 . available E1 . This new route results in accep- 48 Climacteric Estetrol review Coelingh Bennink, Holinka and Diczfalusy 36 table yields of E4 of very high purity (498%) different . Metabolites produced by rat hepato- without contamination with E2. It permits the cytes were not found with human hepatocytes and synthesis of E4 on a (semi)-industrial scale suitable vice versa. In rat hepatocytes, phase I metabolism for GMP (Good Manufacturing Production) for is most important. This may result in active human use35. This new method overcomes the metabolites in the rat, whereas inactivation by disadvantages of previous methods. glucuronidation and sulfation, i.e. phase II meta- Pharmaceutical studies revealed that E4 is bolism, are the pathways observed in human chemically very stable even under non-optimal hepatocytes36. This confirms that, in the human, 34 storage conditions . It has high water solubility E4 is an end-stage product of metabolism and has and might be slightly hygroscopic. Estetrol has no active metabolites. an octanol–water parturition coefficient (Pow) of Estetrol at a high concentration of 10 mmol/l did about 1.5, making it about a 100-fold less not inhibit the major cytochrome P450 enzymes lipophylic than E2 or ethinylestradiol. As a CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP Pow of 2 is considered optimal for passage 3A436. Estradiol and ethinylestradiol significantly through the blood–brain barrier, E4 might be inhibited CYP2C19. Ethinylestradiol had a strong expected to have effects on the central nervous inhibitory effect on CYP3A4, whereas E2 stimu- system. lated this enzyme significantly and E4 had some 36 It is concluded that, with this new method, E4 stimulatory effect . These results suggest that E4 can be synthesized consistently with high purity may exhibit less interference with concomitantly and without important contaminations. Estetrol administered drugs (drug–drug interaction) com- appears to have very favorable properties for the pared to ethinylestradiol and E2. development of a pharmaceutical product. The ERa-dependent effect of the steroids E2,E3, E4 and ethinylestradiol on sex hormone binding globulin (SHBG) production was investigated RECEPTOR BINDING AND TARGET using the HepG2 and Hep89 cell lines39. Estetrol INTERACTION did not stimulate the production of SHBG in both Estetrol has a moderate affinity for human cell lines, suggesting that E4 may not influence the estrogen a receptor (ERa) and estrogen b receptor plasma levels of SHBG. The estrogens E2,E3 and (ERb), with Ki values of 4.9 + 0.567 nmol/l and ethinylestradiol all show a dose-dependent ERa- 19 + 1 nmol/l, respectively, demonstrating a four- mediated increase in the production of SHBG. to five-fold preference for the ERa (lower Ki This increase in SHBG production is most For personal use only. 36 value) . prominent for E2, while addition of E3 and Estetrol has high selectivity for the estrogen ethinylestradiol resulted in a lower and compar- receptors. Binding at the glucocorticoid, proges- able increase in SHBG. Binding of E4 to SHBG terone and testosterone receptors was only was also studied in vitro39. There was no 11–15% at a concentration of 10 mmol/l and detectable binding of E4 to the estrogenic and further profiling of E4 in a set of 124 receptors and androgenic human SHBG steroid-binding sites enzymes demonstrated inactivity towards 123 (Figure 2). By contrast, testosterone and E2 were molecular targets. The single target showing bound with high affinity, whereas the synthetic interaction with E4 was the adrenergic a1b estrogen ethinylestradiol binds to SHBG with low receptor (weak binding)36. affinity39. These data indicate that SHBG has no Climacteric Downloaded from informahealthcare.com by University of California Irvine on 11/08/14 It is concluded that genomic clinical effects of influence on the plasma distribution of E4 or its E4 will most likely occur through the estrogen availability to target tissues, contrary to other receptors.
Load more

Recommended publications
  • Memorandum Date: June 6, 2014
    DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Memorandum Date: June 6, 2014 From: Bisphenol A (BPA) Joint Emerging Science Working Group Smita Baid Abraham, M.D. ∂, M. M. Cecilia Aguila, D.V.M. ⌂, Steven Anderson, Ph.D., M.P.P.€* , Jason Aungst, Ph.D.£*, John Bowyer, Ph.D. ∞, Ronald P Brown, M.S., D.A.B.T.¥, Karim A. Calis, Pharm.D., M.P.H. ∂, Luísa Camacho, Ph.D. ∞, Jamie Carpenter, Ph.D.¥, William H. Chong, M.D. ∂, Chrissy J Cochran, Ph.D.¥, Barry Delclos, Ph.D.∞, Daniel Doerge, Ph.D.∞, Dongyi (Tony) Du, M.D., Ph.D. ¥, Sherry Ferguson, Ph.D.∞, Jeffrey Fisher, Ph.D.∞, Suzanne Fitzpatrick, Ph.D. D.A.B.T. £, Qian Graves, Ph.D.£, Yan Gu, Ph.D.£, Ji Guo, Ph.D.¥, Deborah Hansen, Ph.D. ∞, Laura Hungerford, D.V.M., Ph.D.⌂, Nathan S Ivey, Ph.D. ¥, Abigail C Jacobs, Ph.D.∂, Elizabeth Katz, Ph.D. ¥, Hyon Kwon, Pharm.D. ∂, Ifthekar Mahmood, Ph.D. ∂, Leslie McKinney, Ph.D.∂, Robert Mitkus, Ph.D., D.A.B.T.€, Gregory Noonan, Ph.D. £, Allison O’Neill, M.A. ¥, Penelope Rice, Ph.D., D.A.B.T. £, Mary Shackelford, Ph.D. £, Evi Struble, Ph.D.€, Yelizaveta Torosyan, Ph.D. ¥, Beverly Wolpert, Ph.D.£, Hong Yang, Ph.D.€, Lisa B Yanoff, M.D.∂ *Co-Chair, € Center for Biologics Evaluation & Research, £ Center for Food Safety and Applied Nutrition, ∂ Center for Drug Evaluation and Research, ¥ Center for Devices and Radiological Health, ∞ National Center for Toxicological Research, ⌂ Center for Veterinary Medicine Subject: 2014 Updated Review of Literature and Data on Bisphenol A (CAS RN 80-05-7) To: FDA Chemical and Environmental Science Council (CESC) Office of the Commissioner Attn: Stephen M.
    [Show full text]
  • Estetrol: New Perspectives for HRT in Menopause and Breast Cancer
    Graziottin A. Singer C. Kubista E. Visser M. Coelingh Bennink H. Estetrol: new perspectives for HRT in menopause and breast cancer patients V Annual International Congress on Human Reproduction on "Family Reproductive Health", Moscow, Russia, January 18-21, 2011 Estetrol: new perspectives for HRT in menopause and breast cancer patients Alessandra Graziottin *, Christian Singer **, Ernst Kubista **, Monique Visser *** and Herjan J.T. Coelingh Bennink *** * Professor at the University of Florence, Italy – Director, Center of Gynaecology, H San Raffaele Resnati, Milan, Italy ** Akademisches Krankenhaus Wien, Wien, Austria *** Pantarhei Bioscience, Zeist, The Netherlands Estetrol (E 4) is a foetal estrogen, produced by the foetal liver during pregnancy only. It has a selective ERalpha and ERbeta receptor bindin g with preference for ERalpha, with antagonist action. E 4 is present at 9 weeks of gestation, with exponential increase of synthesis and blood levels. At term the foetus produces about 3 mg/day. Elimination half-life is 28 hours. Potential applications in women’s life-span include: contraception, hormone replacement therapy (HRT), specifically for vasomotor symptoms, vulvovaginal atrophy and osteoporosis, and therapy of breast cancer. Preliminary data support its efficacy in the treatment of: hot flushes, with significant reduction; in the maturation of the vaginal mucosa, with significant increase of superficial cells at the cytological evaluation; a dose dependent effect on the endometrium: low doses such as 2 mg of Estetrol/day, sufficient to treat a number of symptoms, do not stimulate the endometrium; a significant protective effect on bone: this growing set of data suggest that E 4 could have a new, significant role in the treatment of menopausal symptoms, with an extraordinary safe profile.
    [Show full text]
  • Failures and Controversies of the Antiestrogen Treatment of Breast Cancer
    In: Estrogen Prevention for Breast Cancer ISBN: 978-1-62417-378-3 Editor: Zsuzsanna Suba © 2013 Nova Science Publishers, Inc. No part of this digital document may be reproduced, stored in a retrieval system or transmitted commercially in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services. Chapter VII Failures and Controversies of the Antiestrogen Treatment of Breast Cancer Zsuzsanna Suba National Institute of Oncology, Department of Surgical and Molecular Pathology, Budapest, Hungary Abstract In postmenopausal women, estrogens have unquestionable preventive and curative effects against atherogenic cardiovascular lesions, osteoporosis and neurodegenerative diseases. Moreover, recent studies on correlations between hormone replacement therapy and cancer risk could justify preventive, anticancer capacities of estrogen both on smoking associated and hormone related cancers. Experimental developing of antiestrogen compounds aimed to inhibit the binding of presumably harmful, endogenous estrogen to its receptor system so as to achieve a regression of hormone-related cancers. However, antiestrogens proved to be ineffective in the majority of selected receptor positive breast cancer cases and produced severe side effects, such as vascular complications and cancer development at several sites. Failure of antiestrogen therapy was designated as ―endocrine resistance‖ of tumors.
    [Show full text]
  • NDA/BLA Multi-Disciplinary Review and Evaluation
    NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) NDA/BLA Multi-Disciplinary Review and Evaluation Application Type NDA Application Number(s) NDA 214154 (IND 110682) Priority or Standard Standard Submit Date(s) April 15, 2020 Received Date(s) April 15, 2020 PDUFA Goal Date April 15, 2021 Division/Office Division of Urology, Obstetrics, and Gynecology (DUOG) / Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine (ORPURM) Review Completion Date April 15, 2021 Established/Proper Name drospirenone and estetrol tablets (Proposed) Trade Name Nextstellis Pharmacologic Class Combination hormonal contraceptive Applicant Mayne Pharma LLC Dosage form Tablet Applicant proposed Dosing x Take one tablet by mouth at the same time every day. Regimen x Take tablets in the order directed on the blister pack. Applicant Proposed For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy Recommendation on Approval Regulatory Action Recommended For use by females of reproductive potential to prevent Indication(s)/Population(s) pregnancy (if applicable) Recommended Dosing x Take one pink tablet (drospirenone 3 mg, estetrol Regimen anhydrous 14.2 mg) by mouth at the same time every day for 24 days x Take one white inert tablet (placebo) by mouth at the same time every day for 4 days following the pink tablets x Take tablets in the order directed on the blister pack 1 Reference ID: 4778993 NDA/BLA Multi-disciplinary Review and Evaluation NDA 214154 Nextstellis (drospirenone and estetrol tablets) Table of Contents Table of Tables .................................................................................................................... 5 Table of Figures ................................................................................................................... 7 Reviewers of Multi-Disciplinary Review and Evaluation ...................................................
    [Show full text]
  • 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : the Unique Potential of Estetrol
    investor day 2016 29 June 2016 09 :30 – 09 :55 : Registration 09 :55 – 10 :00 : Welcome 10 :00 – 10 :30 : The unique potential of Estetrol 10 :30 – 11 :45Programme: Mithra’sde la journée strategy 11 :45 – 12 :00 : Q&A 12 :00 – 13 :30 : Drink and lunch with Executive Management 13 :30 – 14 :15 : Focus on Estetrol-based projects 14 :15 – 14 :30 : Coffee break 14 :30 – 15 :15 : Focus on long-acting drugs and Mithra CDMO 15 :15 – 15 :30 : Q&A and wrap-up session 15 :30 – 16 :30 : Drink and networking What is Estetrol ? Interview with Professor J.M. Foidart MD. Member of scientific committee Mithra Professor J.M. Foidart MD. Member of scientific committee Mithra 4 Estrogens in the “pill” a very limited family . Estradiol . Synthetic progestin . Ethinylestradiol Over 95% of oral contraceptives contain ethinylestradiol 6 Synthetic Progestins : a very large family First First Second Third New” COCs generation: generation: generation: progestins: > Norethisterone > Norethynodrel > Norgestrel > Desogestrel > Drospirenone > Norethinodrel > Nortestosterone > Levonorgestrel > Etonogestrel > Dienogest > High doses of derivatives > Gestodene > Trimestone synthetic estrogen >Pregnanes > Nesterone and androgenic > Norgestimate > Nomegestrol Ac. progestin > Promegestone Jan 2014 EMA classification progestins by type . Structural modification: to reduce androgenic side-effects but maintain strong progestational activity . Wider health benefits depending on progestin properties Reviewed in Brynhildsen J. Ther Adv Drug Saf. 2014;5(5):201-13; Benagiano7 G, et al. Eur J Contracept Reprod Health Care. 2004;9(3):182- 93; Sitruk-Ware R. Hum Reprod Update. 2006;12(2):169-78; Micks E, et al. Endocr Connect. 2015;4(4):R81-92 The third and fourth generation progestins and pills are not androgenic.
    [Show full text]
  • A Phosphotyrosyl Peptide That Blocks Dimerization of the Human Estrogen Receptor (Estradiol/MCF-7 Cells/Tyrosine Phosphorylation/Dimerization/DNA Binding) STEVEN F
    Proc. Natl. Acad. Sci. USA Vol. 92, pp. 7475-7479, August 1995 Biochemistry An antiestrogen: A phosphotyrosyl peptide that blocks dimerization of the human estrogen receptor (estradiol/MCF-7 cells/tyrosine phosphorylation/dimerization/DNA binding) STEVEN F. ARNOLD AND ANGELO C. NOTIDES* Departments of Environmental Medicine and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642 Communicated by Jack Gorski, University of Wisconsin, Madison, WI, April 28, 1995 (received for review January 13, 1995) ABSTRACT We have previously identified tyrosine-537 scription (STAT) bind DNA as dimers through a reciprocal as a constitutively phosphorylated site on the human estrogen association of a phosphotyrosine on one monomer with a Src receptor (hER). A 12-amino acid phosphotyrosyl peptide homology 2 domain (SH2 domain) on the complementary containing a selected sequence surrounding tyrosine-537 was monomer (15, 16). used to investigate the function of phosphotyrosine-537. The Deletion and mutational analyses have provided evidence phosphotyrosyl peptide completely blocked the binding of the that the C terminus of the steroid hormone receptors is hER to an estrogen response element (ERE) in a gel mobility necessary for receptor dimerization (4). The dimerization of shift assay. Neither the nonphosphorylated tyrosyl peptide the nuclear hormone receptors is reported to be regulated by nor an unrelated phosphotyrosyl peptide previously shown to hydrophobic heptad repeats in the C terminus (17, 18). A inhibit the signal transducers and activators of transcription 22-amino acid sequence from positions 501 to 522 in the C factor (STAT) blocked binding of the hER to the ERE. The terminus of the mouse estrogen receptor was isolated that hER phosphotyrosyl peptide was shown by molecular sizing conferred DNA binding to DNA-binding-deficient mutants chromatography to dissociate the hER dimer into monomers.
    [Show full text]
  • The Structural Biology of Oestrogen Metabolism
    Journal of Steroid Biochemistry & Molecular Biology 137 (2013) 27–49 Contents lists available at ScienceDirect Journal of Steroid Biochemistry and Molecular Biology jo urnal homepage: www.elsevier.com/locate/jsbmb Review The structural biology of oestrogen metabolism ∗ Mark P. Thomas, Barry V.L. Potter Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath, BA2 7AY, UK a r t i c l e i n f o a b s t r a c t Article history: Many enzymes catalyse reactions that have an oestrogen as a substrate and/or a product. The reac- Received 11 September 2012 tions catalysed include aromatisation, oxidation, reduction, sulfonation, desulfonation, hydroxylation Received in revised form and methoxylation. The enzymes that catalyse these reactions must all recognise and bind oestrogen but, 10 December 2012 despite this, they have diverse structures. This review looks at each of these enzymes in turn, describing Accepted 12 December 2012 the structure and discussing the mechanism of the catalysed reaction. Since oestrogen has a role in many disease states inhibition of the enzymes of oestrogen metabolism may have an impact on the state or Keywords: progression of the disease and inhibitors of these enzymes are briefly discussed. Oestrogen This article is part of a Special Issue entitled ‘CSR 2013’. Protein structure © 2012 Elsevier Ltd. Open access under CC BY license. Reaction mechanism Aromatase Sulfatase Sulfotransferase 17␤-Hydroxysteroid dehydrogenase Contents 1. Introduction . 27 2. Methods . 29 3. Oestrogen sulfotransferase . 29 4. Steroid sulfatase. 31 5. 17␤-Hydroxysteroid dehydrogenases . 33 6. Aromatase (cytochrome P450 19A1, oestrogen synthase) . 36 7. Enzymes of steroid hydroxylation .
    [Show full text]
  • Health Plan Insights
    Health Plan Insights September 2020 Updates from August 2020 Confidential – Do not copy or distribute. 800-361-4542 | elixirsolutions.com 1 Recent FDA Approvals New Medications TRADE NAME DOSAGE FORM APPROVAL MANUFACTURER INDICATION(S) (generic name) STRENGTH DATE Blenrep GlaxoSmithKline Injection, For the treatment of adult patients with August 5, 2020 (belantamab 2.5 mg/kg relapsed or refractory multiple myeloma who mafodotin-blmf) have received at least 4 prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. Lampit Bayer Healthcare Tablets, For use in pediatric patients (birth to less than August 6, 2020 (nifurtimox) 30 mg and 120 18 years of age and weighing at least 2.5 kg) mg for the treatment of Chagas disease (American Trypanosomiasis), caused by Trypanosoma cruzi. Olinvyk Trevena, Inc. Injection, For use in adults for the management of August 7, 2020 (oliceridine) 1 mg/mL acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Evrysdi Genentech, Inc. Oral Solution, For the treatment of spinal muscular atrophy August 7, 2020 (risdiplam) 0.75 mg/mL (SMA) in patients 2 months of age and older. Viltepso NS Pharma, Inc. Injection, For the treatment of Duchenne muscular August 12, 2020 (viltolarsen) 50 mg/mL dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
    [Show full text]
  • Use of Aromatase Inhibitors in Breast Carcinoma
    Endocrine-Related Cancer (1999) 6 75-92 Use of aromatase inhibitors in breast carcinoma R J Santen and H A Harvey1 Department of Medicine, University of Virginia Health Sciences Center, Charlottesville, Virginia 22908, USA 1Department of Medicine, Penn State College of Medicine, Hershey, Pennsylvania 17033, USA (Requests for offprints should be addressed to R J Santen) Abstract Aromatase, a cytochrome P-450 enzyme that catalyzes the conversion of androgens to estrogens, is the major mechanism of estrogen synthesis in the post-menopausal woman. We review some of the recent scientific advances which shed light on the biologic significance, physiology, expression and regulation of aromatase in breast tissue. Inhibition of aromatase, the terminal step in estrogen biosynthesis, provides a way of treating hormone-dependent breast cancer in older patients. Aminoglutethimide was the first widely used aromatase inhibitor but had several clinical drawbacks. Newer agents are considerably more selective, more potent, less toxic and easier to use in the clinical setting. This article reviews the clinical data supporting the use of the potent, oral competitive aromatase inhibitors anastrozole, letrozole and vorozole and the irreversible inhibitors 4-OH andro- stenedione and exemestane. The more potent compounds inhibit both peripheral and intra-tumoral aromatase. We discuss the evidence supporting the notion that aromatase inhibitors lack cross- resistance with antiestrogens and suggest that the newer, more potent compounds may have a particular application in breast cancer treatment in a setting of adaptive hypersensitivity to estrogens. Currently available aromatase inhibitors are safe and effective in the management of hormone- dependent breast cancer in post-menopausal women failing antiestrogen therapy and should now be used before progestational agents.
    [Show full text]
  • Network-Based Characterization of Drug-Protein Interaction Signatures
    Tabei et al. BMC Systems Biology 2019, 13(Suppl 2):39 https://doi.org/10.1186/s12918-019-0691-1 RESEARCH Open Access Network-based characterization of drug-protein interaction signatures with a space-efficient approach Yasuo Tabei1*, Masaaki Kotera2, Ryusuke Sawada3 and Yoshihiro Yamanishi3,4 From The 17th Asia Pacific Bioinformatics Conference (APBC 2019) Wuhan, China. 14–16 January 2019 Abstract Background: Characterization of drug-protein interaction networks with biological features has recently become challenging in recent pharmaceutical science toward a better understanding of polypharmacology. Results: We present a novel method for systematic analyses of the underlying features characteristic of drug-protein interaction networks, which we call “drug-protein interaction signatures” from the integration of large-scale heterogeneous data of drugs and proteins. We develop a new efficient algorithm for extracting informative drug- protein interaction signatures from the integration of large-scale heterogeneous data of drugs and proteins, which is made possible by space-efficient representations for fingerprints of drug-protein pairs and sparsity-induced classifiers. Conclusions: Our method infers a set of drug-protein interaction signatures consisting of the associations between drug chemical substructures, adverse drug reactions, protein domains, biological pathways, and pathway modules. We argue the these signatures are biologically meaningful and useful for predicting unknown drug-protein interactions and are expected to contribute to rational drug design. Keywords: Drug-protein interaction prediction, Drug discovery, Large-scale prediction Background similar drugs are expected to interact with similar pro- Target proteins of drug molecules are classified into a pri- teins, with which the similarity of drugs and proteins are mary target and off-targets.
    [Show full text]
  • Estetrol for Menopause Symptoms: the Cinderella of Estrogens Or Just Another Fairy Tale? Nancy King Reame, MSN, Phd, FAAN
    CE: D.C.; MENO-D-20-00177; Total nos of Pages: 3; MENO-D-20-00177 Menopause: The Journal of The North American Menopause Society Vol. 27, No. 8, pp. 000-000 DOI: 10.1097/GME.0000000000001601 ß 2020 by The North American Menopause Society EDITORIAL Estetrol for menopause symptoms: the Cinderella of estrogens or just another fairy tale? Nancy King Reame, MSN, PhD, FAAN espite the advent of lower dosing, transdermal deliv- affinity (<5%) compared to E2.3 Interest was, however, ery, and targeted use in younger age groups, safety renewed in the 2000s when preclinical and pharmacokinetic D concerns persist regarding the potential for estrogen- studies showed that estetrol elicits considerable estrogenic based menopause hormone therapy (MHT) to raise breast effects in rat models for both hot flashes and bone loss, but cancer and thromboembolism risk. In the last few decades a with minimal stimulation of liver and breast.4 More recent wealth of scientific advances has revealed the molecular biol- translational studies5 showed that E4 was bestowed with an ogy of the estrogen receptors (ERs) a and b, opening up new intriguing ER pharmacology, unique from SERMs, thus directions for their pharmaceutical manipulation and promise pushing it to center stage for its potential as the first native to improve hormone therapies. With the help of the ER knock- estrogen with selective action in tissues (NEST). out mouse model, an array of estrogen-mediated actions in Unlike other estrogens, which interact with both a and b tissues throughout the body was elucidated, followed by the receptors at the cell surface and in the nucleus, E4 not only emergence of new compounds with tissue-dependent, ER preferentially binds to the ERa subtype, but does so in a distinct agonistic, antagonistic, and mixed actions.1 Although several non-SERM way.
    [Show full text]
  • Editorial.Final 10/20/06 1:39 PM Page 10
    OBG_11.06_Editorial.final 10/20/06 1:39 PM Page 10 EDITORIAL Is Premarin actually a SERM? It acts like a SERM... onjugated equine estrogen Effects of tamoxifen and Premarin (Premarin) has historically been Initially, tamoxifen was characterized as an C characterized as an estrogen ago- “anti-estrogen,” but it is now recognized nist. But the report from the Women’s that tamoxifen has mixed properties. It is an Health Initiative that long-term Premarin estrogen antagonist in some tissues (breast) Robert L. Barbieri, MD Editor-in-Chief treatment is associated with a reduced risk and an estrogen agonist in other tissues of breast cancer raises the possibility that (bone). To recognize these mixed estrogen Premarin may have both estrogen agonist agonist–antagonist properties, tamoxifen is and antagonist properties. Premarin may now categorized as a SERM. Premarin and actually be better categorized as a selective tamoxifen share many similarities in their estrogen receptor modulator (SERM). effects on major clinical outcomes in post- ® Dowden Healthmenopausal Media women (Table, page 13), WHI: Premarin vs placebo including their effects on breast and In the Premarin vs placebo arm, approximately endometrial cancer, deep venous thrombo- 10,800Copyright postmenopausalFor personal women with ause prior onlysis, and osteoporotic fracture. One clinical- hysterectomy who were 50 to 79 years of age ly important divergence is that tamoxifen were randomized to Premarin 0.625 mg daily or increases and Premarin decreases vasomo- an identical-appearing placebo.1 After a mean tor symptoms. FAST TRACK follow-up of 7.1 years, the risk of invasive breast Commonly used medications that inter- In any case, cancer in the women treated with Premarin was act with the estrogen receptor can be 0.80 (95% confidence interval [CI], 0.62–1.04, arranged along a continuum from a “pure” “Use the lowest P=.09).
    [Show full text]